Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar biostrategy (< 20) Submitted: 11/4/2013 9:34:06 AM : Outperform Start Price: $150.68 CELG Score: -11.43

Excellent Product Portfolio Performance and Finance Position

Featured Broker Partners


Advertisement